CN106068127B - 蛋白质的硫醚缀合方法 - Google Patents

蛋白质的硫醚缀合方法 Download PDF

Info

Publication number
CN106068127B
CN106068127B CN201480068335.5A CN201480068335A CN106068127B CN 106068127 B CN106068127 B CN 106068127B CN 201480068335 A CN201480068335 A CN 201480068335A CN 106068127 B CN106068127 B CN 106068127B
Authority
CN
China
Prior art keywords
protein
chemical moiety
conjugation
solution
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480068335.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN106068127A (zh
Inventor
C.S.亨內彻
T.B.汉森
E.B.汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk Health Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care AG filed Critical Novo Nordisk Health Care AG
Publication of CN106068127A publication Critical patent/CN106068127A/zh
Application granted granted Critical
Publication of CN106068127B publication Critical patent/CN106068127B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480068335.5A 2013-12-13 2014-12-15 蛋白质的硫醚缀合方法 Active CN106068127B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13197150 2013-12-13
EP13197150.9 2013-12-13
PCT/EP2014/077777 WO2015086853A1 (en) 2013-12-13 2014-12-15 Method for thioether conjugation of proteins

Publications (2)

Publication Number Publication Date
CN106068127A CN106068127A (zh) 2016-11-02
CN106068127B true CN106068127B (zh) 2020-06-19

Family

ID=49765887

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480068335.5A Active CN106068127B (zh) 2013-12-13 2014-12-15 蛋白质的硫醚缀合方法

Country Status (6)

Country Link
US (1) US11219690B2 (cg-RX-API-DMAC7.html)
EP (1) EP3079722B1 (cg-RX-API-DMAC7.html)
JP (1) JP6603662B2 (cg-RX-API-DMAC7.html)
CN (1) CN106068127B (cg-RX-API-DMAC7.html)
ES (1) ES2869309T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015086853A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117106085A (zh) 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
EP4480537A3 (en) 2017-01-17 2025-03-12 Amgen Inc. Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
CA3062194A1 (en) 2017-06-20 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
MA68842B1 (fr) * 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1210400C (zh) * 1999-01-14 2005-07-13 博尔德生物技术公司 制备含游离半胱氨酸残基的蛋白质的方法
WO2006134173A2 (en) * 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
CN101212984A (zh) * 2005-07-06 2008-07-02 Ucb医药有限公司 连接效应分子与蛋白质的方法
CN103002918A (zh) * 2010-01-22 2013-03-27 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
CN103087183A (zh) * 2013-01-17 2013-05-08 南京邮电大学 一种光激发蛋白质中二硫键还原得到自由巯基的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2004101597A2 (en) 2003-05-13 2004-11-25 Frutarom Ltd. Methods for the reduction of disulfide bonds
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
WO2007109475A2 (en) * 2006-03-16 2007-09-27 Bracco Imaging S.P.A. Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
JP5703020B2 (ja) 2007-08-24 2015-04-15 ノボ ノルディスク ヘルス ケア アーゲー タンパク質を選択的に修飾するための組成物と方法
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
ES2582590T3 (es) 2010-02-16 2016-09-13 Novo Nordisk A/S Método de purificación
CN103269720A (zh) 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
EP3412314A1 (en) 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
KR20140091721A (ko) * 2011-11-02 2014-07-22 제넨테크, 인크. 오버로드 및 용리 크로마토그래피

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1210400C (zh) * 1999-01-14 2005-07-13 博尔德生物技术公司 制备含游离半胱氨酸残基的蛋白质的方法
WO2006134173A2 (en) * 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
CN101212984A (zh) * 2005-07-06 2008-07-02 Ucb医药有限公司 连接效应分子与蛋白质的方法
CN103002918A (zh) * 2010-01-22 2013-03-27 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
CN103087183A (zh) * 2013-01-17 2013-05-08 南京邮电大学 一种光激发蛋白质中二硫键还原得到自由巯基的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Technology trends in antibody purification";Pete Gagnon;《 J. Chromatogr. A》;20111020;第1221卷;第57-70页 *

Also Published As

Publication number Publication date
JP6603662B2 (ja) 2019-11-06
EP3079722A1 (en) 2016-10-19
WO2015086853A1 (en) 2015-06-18
US11219690B2 (en) 2022-01-11
ES2869309T3 (es) 2021-10-25
US20160303248A1 (en) 2016-10-20
EP3079722B1 (en) 2021-03-24
CN106068127A (zh) 2016-11-02
JP2017501148A (ja) 2017-01-12

Similar Documents

Publication Publication Date Title
FI113272B (fi) Parannettu proteiinien laskostamismenetelmä
Liebner et al. Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra
JP6603662B2 (ja) タンパク質のチオエーテルコンジュゲーション方法
ES2870802T3 (es) Métodos de replegado de proteínas a elevado pH
WO1999033988A1 (en) A process for preparing human proinsulin
ES2813501T3 (es) Métodos de replegado de proteínas basados en filtración de flujo tangencial
CN104926924A (zh) 一种利用手性锍盐侧链稳定多肽α-螺旋二级结构的方法
CN103923209A (zh) 一种Lambda干扰素突变体及聚乙二醇衍生物
CN101173006B (zh) 一种重组人胰岛素的制备方法
CN105732820A (zh) 一种重组人胰岛素原融合蛋白的复性方法
JP2017501148A5 (cg-RX-API-DMAC7.html)
CN108610415A (zh) 一种抗体复合物的制备方法
JP4088584B2 (ja) 融合タンパク質から目的タンパク質を分離する方法。
CN105085658A (zh) 一种白细胞介素29突变体及聚乙二醇衍生物
CN100387614C (zh) 包涵体蛋白复性并同时纯化的方法
JP2022511951A5 (cg-RX-API-DMAC7.html)
CN106632588A (zh) 一种聚乙二醇修饰蛋白的纯化工艺
CN100493615C (zh) 一种单修饰的聚乙二醇化胰岛素及其制备方法
CN104945498A (zh) 长效化PEG-rExendin-4改构体偶联物的制备
CN100589844C (zh) 一种单修饰的聚乙二醇-胰岛素复合物及其制备方法
CN118451086A (zh) 一种蛋白和/或多肽糖基化修饰的方法
JP5713006B2 (ja) チオスルホナート化合物、タンパク質及び/又はペプチドの可逆的カチオン化剤並びに可溶化方法
CN103333238A (zh) 一种mPEG-MAL-aGLP-1复合物
CN115651070B (zh) 链间二硫键CysA24-CysB23替代为硫醚键的H2 Relaxin衍生物
CN102585012B (zh) 一种石斑鱼α干扰素衍生物的制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant